CLOFAZIMINE: 4,433 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
4,433
Total FAERS Reports
1,021 (23.0%)
Deaths Reported
1,528
Hospitalizations
4,433
As Primary/Secondary Suspect
275
Life-Threatening
127
Disabilities
Dec 15, 1986
FDA Approved
Discontinued
Status
FDA Application: 019500 ·
First Report: 19820723 · Latest Report: 20250821
What Are the Most Common CLOFAZIMINE Side Effects?
#1 Most Reported
Electrocardiogram qt prolonged
629 reports (14.2%)
#2 Most Reported
Nausea
403 reports (9.1%)
#3 Most Reported
Vomiting
399 reports (9.0%)
All CLOFAZIMINE Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Electrocardiogram qt prolonged | 629 | 14.2% | 107 | 223 |
| Nausea | 403 | 9.1% | 58 | 185 |
| Vomiting | 399 | 9.0% | 107 | 192 |
| Off label use | 389 | 8.8% | 93 | 151 |
| Anaemia | 353 | 8.0% | 81 | 182 |
| Dyspnoea | 313 | 7.1% | 142 | 190 |
| Neuropathy peripheral | 238 | 5.4% | 34 | 62 |
| Diarrhoea | 213 | 4.8% | 53 | 97 |
| Drug resistance | 196 | 4.4% | 12 | 47 |
| Drug ineffective | 191 | 4.3% | 26 | 44 |
| Cough | 173 | 3.9% | 31 | 87 |
| Product use in unapproved indication | 173 | 3.9% | 25 | 33 |
| Asthenia | 171 | 3.9% | 65 | 94 |
| Death | 171 | 3.9% | 171 | 64 |
| Hepatotoxicity | 171 | 3.9% | 8 | 28 |
| Decreased appetite | 162 | 3.7% | 40 | 96 |
| Pyrexia | 161 | 3.6% | 31 | 99 |
| Respiratory failure | 151 | 3.4% | 135 | 76 |
| Aspartate aminotransferase increased | 139 | 3.1% | 40 | 70 |
| Intentional product use issue | 135 | 3.1% | 56 | 65 |
Who Reports CLOFAZIMINE Side Effects? Age & Gender Data
Gender: 47.1% female, 52.9% male. Average age: 44.5 years. Most reports from: US. View detailed demographics →
Is CLOFAZIMINE Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2005 | 1 | 0 | 1 |
| 2008 | 2 | 0 | 0 |
| 2009 | 1 | 0 | 0 |
| 2010 | 1 | 0 | 0 |
| 2011 | 7 | 2 | 6 |
| 2012 | 4 | 0 | 3 |
| 2013 | 2 | 0 | 1 |
| 2014 | 19 | 3 | 7 |
| 2015 | 40 | 7 | 20 |
| 2016 | 126 | 44 | 62 |
| 2017 | 311 | 100 | 164 |
| 2018 | 730 | 255 | 309 |
| 2019 | 599 | 125 | 246 |
| 2020 | 216 | 57 | 82 |
| 2021 | 154 | 27 | 66 |
| 2022 | 181 | 30 | 88 |
| 2023 | 230 | 41 | 91 |
| 2024 | 167 | 31 | 73 |
| 2025 | 53 | 5 | 23 |
What Is CLOFAZIMINE Used For?
| Indication | Reports |
|---|---|
| Tuberculosis | 2,006 |
| Pulmonary tuberculosis | 473 |
| Mycobacterium abscessus infection | 398 |
| Mycobacterium avium complex infection | 374 |
| Product used for unknown indication | 343 |
| Mycobacterial infection | 204 |
| Atypical mycobacterial infection | 98 |
| Lepromatous leprosy | 84 |
| Leprosy | 84 |
| Mycobacterium chelonae infection | 59 |
CLOFAZIMINE vs Alternatives: Which Is Safer?
CLOFAZIMINE vs CLOMETHIAZOLE
CLOFAZIMINE vs CLOMIPHENE
CLOFAZIMINE vs CLOMIPRAMINE
CLOFAZIMINE vs CLONAZEPAM
CLOFAZIMINE vs CLONIDINE
CLOFAZIMINE vs CLOPIDOGREL
CLOFAZIMINE vs CLOPIDOGREL BESILATE
CLOFAZIMINE vs CLOPIDOGREL BISULFATE
CLOFAZIMINE vs CLORAZEPATE
CLOFAZIMINE vs CLOSTRIDIUM TETANI TOXOID ANTIGEN
Official FDA Label for CLOFAZIMINE
Official prescribing information from the FDA-approved drug label.